Перегляд за Автор "Rumiantseva, M. O."

Зараз показуємо 1 - 1 з 1
  • Ескіз недоступний
    Документ
    Chronic obstructive pulmonary disease and comorbidities: management of somatoform disorders
    (Aluna Publishing, Польща, 2021) Burya, L. V.; Kapustianska, A. A.; Moiseieva, N. V.; Vakhnenko, A. V.; Rumiantseva, M. O.; Zviagolska, I. M.; Буря, Лілія Володимирівна; Капустянська, Анна Анатоліївна; Моісєєва, Наталія Віталіївна; Вахненко, Андрій Вікторович; Рум'янцева, Марія Олександрівна; Звягольська, Ірина Миколаївна
    The aim: To perform a comprehensive evaluation of the effect of paroxetine on the degree of somatoform disorders in exacerbation of severe COPD in women. Materials and methods: The study involved 53 female patients with severe COPD (Group D), confirmed by instrumental methods of study. At hospitalization, patients were divided into 2 groups. Patients of Group 1 (n = 21; aged 52.5 ± 0.8 years old) underwent basic exacerbation therapy. Patients of Group 2 (n = 22; aged 57.9 ± 0.4 years old) underwent basic exacerbation therapy supplemented with paroxetine for 14 days, 1 tablet (0.20 g) once a day. Results: The basic therapy for treatment of COPD exacerbations, supplemented with paroxetine, led to a positive clinical effect, confirmed by increase in skeletal and respiratory muscular system, increased parameters of pulmonary ventilation, increased tolerance to physical load, increased oxygen saturation, decreased heart rate and breathing rate. Conclusions: The strategy for choosing an antidepressant to provide multidisciplinary care for somatoform disorders in women with exacerbation of severe COPD (group D) should take into account the efficacy and favorable safety profile and personalization of the drug. In exacerbation of severe COPD, the degree of somatoform disorders in patients correlates with the severity of the main criteria: FVC1, the distance walked during the 6-minute step test, oxygen saturation after the 6-minute step test, end-expiratory pressure in the oral cavity.